KRAS and neoplasm: ,18 After stratification by tumor subtype, we also found that the frequency of KRAS mutations in patients with IHC was higher in our cohort (24.9%) than in previous cohorts (7.4%-12.4%).16, 17, 18,23 Among patients with KRAS mutations, the G12D mutation was the most common in IHC (41.5%), EHC (35.9%), and GB (29.8%), which is consistent with a previous report.17